📰 Key Markers News
Key Markers News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Key Markers. Real-time updates on events, politics, business and more.
October 11, 2023
MATERIAL CHANGE REPORT - Name and Address of Company Cardiol Therapeutics Inc. 2265 Upper Middle Road East, Suite 602 Oakville, Ontario,...
October 10, 2023
Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart...
September 21, 2023
/PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of...
June 5, 2023
Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX... | June 5, 2023
May 30, 2023
Or How Critical Thinking Is Deleted in “The Decade That Cannot Be Deleted”
November 7, 2022
Late-breaking abstract selected by AASLD as one of the "Best of the Liver Meeting" for 2022 Phase 2 for PXL065 in NASH achieved the primary efficacy endpoint for liver fat content reduction
September 21, 2022
PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed
September 13, 2022
50mg (41%) and 28mg (39%) groups demonstrated =1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution